MT Newswires
Anixa Biosciences Says Breast Cancer Vaccine Candidate Meets Key Endpoints in Phase 1 Trial
➖
AI Sentiment
Neutral
5/10
- Home
- ANIX
as of 12-12-2025 3:43pm EST
$3.59
$1.21
-25.21%
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Chart Type:
Time Range:
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 135.3M | IPO Year: | 1987 |
| Target Price: | $9.00 | AVG Volume (30 days): | 353.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.07 - $5.46 | Next Earning Date: | 01-09-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ANIX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 57.53%
57.53%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Anixa Biosciences Inc. News
ANIX Breaking Stock News: Dive into ANIX Ticker-Specific Updates for Smart Investing
PR Newswire
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
📈
AI Sentiment
Highly Positive
9/10
Yahoo Finance
Federal Reserve: Expect a 'hawkish cut' today as officials look to slow down on interest rate cuts next year
➖
AI Sentiment
Neutral
5/10
PR Newswire
APhA names Thomas E. Menighan as the 2026 Remington Honor Medal recipient
📈
AI Sentiment
Highly Positive
9/10
PR Newswire
Featherlite expands trailer lineup and continues its innovation with launch of new Model 4414 stacker trailer
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Crowley Appoints Megan Davidson as Chief Operating Officer, Succeeding Ray Fitzgerald
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
One of Havertown's Favorite Holiday Traditions - The 2025 Reindeer Romp will be held December 13
📈
AI Sentiment
Highly Positive
8/10
Compare ANIX vs Leading Stocks
See how ANIX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANIX Anixa Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.